Organisms | Evidence |
---|---|
Mesocestoides vogae | |
Chlorocebus aethiops (grivet) | |
Oryctolagus cuniculus (rabbit) | |
Saccharomyces cerevisiae (brewer's yeast) | |
Taenia hydatigena |
Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
---|---|---|---|---|---|---|
C1GALT1 | (not applicable) |
|
Ser/Thr |
|
Ser/Thr | |
ST6GALNAC1 | CMP-Neu5Ac |
|
Ser/Thr |
|
Ser/Thr | |
ST6GALNAC1 | CMP-Neu5Ac |
|
O-glycan Synthesis |
|
O-glycan Synthesis | |
B3GNT6 | UDP-GlcNAc |
|
[alpha]-pNP |
|
[alpha]-pNP |
Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
---|---|---|---|---|---|---|
C1GALT1 | (not applicable) |
|
Ser/Thr |
|
Ser/Thr | |
ST6GALNAC1 | CMP-Neu5Ac |
|
Ser/Thr |
|
Ser/Thr | |
ST6GALNAC4 | CMP-Neu5Ac |
|
benzyl |
|
benzyl | |
ST6GALNAC1 | CMP-Neu5Ac |
|
O-glycan Synthesis |
|
O-glycan Synthesis | |
ST6GALNAC1 | CMP-Neu5Ac |
|
[Ala-Thr(*)-Ala]2-7 |
|
[Ala-Thr(*)-Ala]2-7 |
Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Reference |
---|---|---|---|---|
ST6GALNAC3 | CMP-Neu5Ac |
|
Ser/Thr | |
ST6GAL2 | CMP-Neu5Ac |
|
para-nitrophenol | |
ST6GALNAC2 | CMP-Neu5Ac |
|
benzyl | |
ST6GALNAC1 | CMP-Neu5Ac |
|
[alpha]-Bz | |
ST6GALNAC2 | CMP-Neu5Ac |
|
Ser/Thr |
Pathway Name | Organism |
---|---|
E.coli O101 | Escherichia coli |
E.coli O103 | Escherichia coli |
E.coli O107 | Escherichia coli |
E.coli O112ab | Escherichia coli |
E.coli O112ac | Escherichia coli |
E.coli O116 | Escherichia coli |
E.coli O117 | Escherichia coli |
E.coli O125ab | Escherichia coli |
E.coli O127 | Escherichia coli |
E.coli O128ab-H27 | Escherichia coli |
RES 1b:a-dgal-HEX-1:5 2s:n-acetyl LIN 1:1d(2+1)2n
PubMed ID | Title | First Author | Publication Date | Source |
---|---|---|---|---|
34036742 | Selective Imaging of HClO in the Liver Tissue In Vivo Using a Near‐infrared Hepatocyte‐specific Fluorescent Probe | Jia X | 2021 Jun 07 |
|
34060347 | Safety, Tissue Distribution, and Metabolism of LNA-Containing Antisense Oligonucleotides in Rats | Romero-Palomo F | 2021 Jun 01 |
|
33587824 | Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran—Results of the phase 1 inhibitor cohort | Pasi KJ | 2021 Jun |
|
34327564 | Identification of N-glycans with GalNAc-containing antennae from recombinant HIV trimers by ion mobility and negative ion fragmentation | Harvey DJ | 2021 Jul 30 |
|
34298952 | Glycoproteins Presenting Galactose and N-Acetylgalactosamine in Human Seminal Plasma as Potential Players Involved in Immune Modulation in the Fertilization Process | Szczykutowicz J | 2021 Jul 08 |
|
33358826 | Prolonged cultured human hepatocytes as an in vitro experimental system for the evaluation of potency and duration of activity of RNA therapeutics: Demonstration of prolonged duration of gene silencing effects of a GalNAc-conjugated human hypoxanthine phosphoribosyl transferase (HPRT1) siRNA | Yang Q | 2021 Jul |
|
33941543 | Nonclinical Pharmacokinetics and Absorption, Distribution, Metabolism, and Excretion of Givosiran, the First Approved N-Acetylgalactosamine–Conjugated RNA Interference Therapeutic | Li J | 2021 Jul |
|
33594389 | Givosiran to treat acute porphyria | Honor A | 2021 Jan |
|
32955428 | Light and shadows of the new therapies for haemophilia treatment in the COVID-19 era | Pasca S | 2021 Jan |
|
33460651 | Human Gb3/CD77 synthase produces P1 glycotope-capped N-glycans, which mediate Shiga toxin 1 but not Shiga toxin 2 cell entry | Szymczak-Kulus K | 2021 Jan |
|
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
This work is licensed under Creative Commons Attribution 4.0 International
GlyCosmos Portal v4.2.1
Last updated: April 7, 2025